Ultime notizie per ABVC BioPharma (NASDAQ:ABVC) Azioni

ABVC BioPharma

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

ABVC BioPharma Inc

News

Guidance

Pinnacle West Capital Adjusts 2024 EPS Guidance Upward From $4.60 - $4.80 To  $5.00 - $5.20, Est $4.85

WIIM

Tencent Music shares are trading lower. Barclays initiated coverage on the stock and announced a price target of $16.

Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) ("Nuvini"), a leading B2B SaaS acquirer in Latin America, is pleased to announce the successful close of its latest financing round, consisting of a combination of equity and convertible notes. The financing, led by Nuvini's Founder and CEO, Pierre Schurmann, and existing investors, underscores the company's strategic growth vision.
The convertible notes were secured at a conversion price of $1.10 per share. The premium pricing signals not only the company's founder and investors' belief in the company's resilience and growth potential but also a shared commitment to building a robust foundation for sustainable, long-term expansion.
In addition to this strategic financing milestone, Nuvini is pleased to announce the promotion of Mr José Mario Ribeiro to the role of Chief Operating Officer. Since the announcement of Jose Mario as Board Advisor in August, he has made significant contributions to the company, and his transition to this expanded role will enable Nuvini to accelerate its focus on embedding finance within its portfolio companies, further amplifying operational efficiencies and growth opportunities.

Management

NVNI

Nuvini Appoints José Mario Ribeiro As New Chief Operating Officer

Contracts

REBN

Reborn Coffee Announced It Has Closed Its Acquisition Of A 58% Stake In South Korean Bbang Ssaem Bakery; Terms Not Disclosed

Jones Lang LaSalle shares are trading higher after the company reported better-than-expected Q3 financial results.

The Company's innovative alcohol-reducing beverage, Sure Shot, will be available in 450+ stores across the Chicago area.
JUPITER, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new distribution agreement with Huckster, Inc., a leading Direct-to-Store (DSD) distributor in Illinois, to expand the availability of its innovative alcohol-reducing beverage, Sure Shot, in the metro Chicago market.
Sure Shot, the first beverage of its kind, is specifically formulated to reduce blood alcohol content while enhancing mental clarity. Its unique blend of essential B vitamins, antioxidants, electrolytes, and nootropics supports the body's natural metabolic processes to efficiently process alcohol, reducing blood alcohol content (BAC) in as little as 30 minutes. This innovative approach, backed by a recently awarded patent and positive clinical study results, positions Sure Shot as the ideal choice for health-conscious individuals who enjoy an active social life.

SHOT

Safety Shot Expands Reach In Metro Chicago With New Distribution Agreement With Huckster, Inc.

Keybanc analyst Steve Barger downgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Overweight to Sector Weight.

Downgrades

Analyst Ratings

Keybanc Downgrades Myers Indus to Sector Weight

EFSH

1847 Holdings Signs Definitive Agreement To Acquire A Cabinet, Door & Millwork Manufacturer For $18.75M

SMCI

Super Micro Computer shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and cut its price target on the stock from $50 to $23.

Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) reported quarterly earnings of $3.37 per share which missed the analyst consensus estimate of $3.48 by 3.16 percent. This is a 3.71 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $1.77 billion which missed the analyst consensus estimate of $1.87 billion by 5.65 percent. This is a 7.94 percent increase over sales of $1.64 billion the same period last year.

Earnings

Earnings Misses

Pinnacle West Capital Q3 2024 GAAP EPS $3.37 Misses $3.48 Estimate, Sales $1.77B Miss $1.87B Estimate

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could&nbsp;present an important oncology possibility
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.

Biotech

General

SONN

Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein

ANIX

Anixa Biosciences Sets November 8 For Public Release Of Phase 1 Breast Cancer Vaccine Data At SITC Annual Meeting

TD Cowen analyst Nick Yako maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and raises the price target from $130 to $150.

Price Target

QLYS

TD Cowen Maintains Hold on Qualys, Raises Price Target to $150

FTHM

Fathom Holdings Announced It Has Promoted Joanne Zach To CFO

<ul>
<li>$800 Million AAA-Rated Personal Loan and $200 Million AA-Rated Auto Loan Asset Backed Securitizations, with $5.5 Billion raised across all ABS transactions year-to-date</li>
<li>Pagaya remains the #1 personal loan ABS issuer in the U.S.</li>
</ul>
Pagaya Technologies LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) ("Pagaya" or "the Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of PAID 2024-10 and RPM 2024-3, totaling $1 billion in size across both deals. This represents the Company's fourth AAA-rated personal loan ABS transaction and its first AA-rated auto ABS transaction.
A total of 28 unique investors participated across these two transactions, the majority of which were repeat investors. The deal was substantially oversubscribed, reflecting continued strong investor demand for Pagaya's robust, AI-enabled consumer credit assets.
Pagaya continues to meet the needs of prominent financial institutions and deliver efficient, fit-for-market structures across the financial ecosystem. Qualified institutional buyers purchased notes backed by personal and auto loans that will be originated by Pagaya's lending partners on Pagaya's AI-powered network.

Pagaya Raises $1B Across Two New Personal Loan And Auto ABS Deals, Signaling Strong Capital Markets Demand; A Total Of 28 Investors Participated Across These Two Transactions, The Majority Of Which Were Repeat Investors

Cummins shares are trading higher after Baird raised its price target on the stock from $330 to $372.

MFA Finl Q3 2024 Distributable EPS $0.37, NII $50.625M

GlobalFoundries shares are trading higher. Baird maintained an Outperform rating on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

TSLA

Tesla shares are trading higher following Donald Trump's successful presidential election campaign.

BACK, ZPTA and ABVC are among premarket gainers

PHG, IBRX and MESO are among premarket gainers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the first quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -40 cents.</li><li>The company reported revenue of $1,205.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/abvc-stock-earnings-abvc-biopharma-for-q1-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024

ABVC Biopharma files to sell 1M shares of common stock for holders

ABVC BioPharma, Inc. (ABVC) has issued an update. ABVC BioPharma has announced corrections to a previous press release concerning their licensing d...

ABVC BioPharma Corrects Licensing Deal Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ABVC BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/abvc-stock-quote/">ABVC</a>) just reported results for the second quarter of 2024.<ul><li>ABVC BioPharma reported earnings per share of -9 cents.</li><li>The company reported revenue of $117,142.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/abvc-stock-earnings-abvc-biopharma-for-q2-of-2024/">ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024

ABVC BioPharma GAAP EPS of -$0.09

An announcement from ABVC BioPharma, Inc. (ABVC) is now available. ABVC BioPharma, Inc. has recently updated its corporate presentation, details of...

ABVC BioPharma Releases Corporate Presentation Update

ABVC BioPharma (ABVC) announced the receipt of an additional $50,000 in licensing fees from AiBtl BioPharma Inc. With this payment, ABVC has receiv...

ABVC BioPharma receives $50,000 in incremental licensing fees

ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb

ABVC

AGBA

BACK

HOLO

HSAI

IBRX

ICLK

MESO

NIVF

SWIN

ZPTA

ZVSA

Press Releases

AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars

ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Health Care

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share

Small Cap

Opinion

Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners

Comments

ABVC BioPharma

Notizie

Ultime notizie per ABVC BioPharma (NASDAQ:ABVC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO